Novo Nordisk and Eli Lilly have soared on the popularity of GLP-1 weight loss drugs. Now Hims & Hers is trying to get in on the action with a more available and affordable option.
Plowing $9 billion into a manufacturing facility could help a successful tirzepatide launch reach new heights.
The gold rush for obesity medications just got a bit more intense.
Will Novo Nordisk top $1 trillion in market value?
The momentum should continue for Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals.
Hims & Hers is a digital health company that is firing on all cylinders, while improving its profit margins at a robust pace.
Novo Nordisk (NVO), the maker of popular weight-loss and diabetes treatments Ozempic and Wegovy, experienced a significant fire at its Danish headquarters in Bagsvaerd, marking the second blaze to impact...
Novo Nordisk's stock may look expensive today, but that may not be the case in even a year or two.
Could Amgen be the next stock to soar due to a GLP-1 drug?
Back then, the company wasn't very well known to U.S. investors. That's absolutely not the case these days.